Galectin Therapeutics (GALT) Retained Earnings (2010 - 2026)
Galectin Therapeutics' quarterly Retained Earnings came in at -$437.6 million in Q1 2026, down 6.43% year-on-year from -$467.7 million in Q1 2025, and down 1.17% quarter-over-quarter from -$432.5 million in Q4 2025.
Galectin Therapeutics has reported Retained Earnings for 17 years, with the latest figure at -$437.6 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 6.43% year-over-year to -$437.6 million; the trailing twelve-month figure through Mar 2026 stood at -$437.6 million (down 6.43% YoY), and the FY2025 full-year result was -$432.5 million, down 7.71% from the prior year.
- Retained Earnings for Q1 2026 stood at -$437.6 million, down from -$432.5 million in the prior quarter.
- The five-year high for Retained Earnings was -$280.6 million in Q1 2022, with the low at -$437.6 million in Q1 2026.
- Average Retained Earnings over 5 years is -$364.2 million, with a median of -$365.9 million recorded in 2024.
- Year-over-year, Retained Earnings fell 15.21% in 2023 and decreased 6.43% in 2026.
- Tracing GALT's Retained Earnings over 5 years: stood at -$309.6 million in 2022, then fell by 14.47% to -$354.4 million in 2023, then retreated by 13.32% to -$401.6 million in 2024, then slipped by 7.71% to -$432.5 million in 2025, then dropped by 1.17% to -$437.6 million in 2026.
- The last three Retained Earnings figures came in at -$437.6 million (Q1 2026), -$432.5 million (Q4 2025), and -$427.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -437.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -437.61 Mn |
| Dec 31, 2025 | -432.55 Mn |
| Sep 30, 2025 | -426.98 Mn |
| Jun 30, 2025 | -418.76 Mn |
| Mar 31, 2025 | -411.18 Mn |
| Dec 31, 2024 | -401.57 Mn |
| Sep 30, 2024 | -389.54 Mn |
| Jun 30, 2024 | -378.30 Mn |
| Mar 31, 2024 | -365.87 Mn |
| Dec 31, 2023 | -354.37 Mn |
| Sep 30, 2023 | -344.31 Mn |
| Jun 30, 2023 | -330.27 Mn |
| Mar 31, 2023 | -321.09 Mn |
| Dec 31, 2022 | -309.57 Mn |
| Sep 30, 2022 | -298.87 Mn |
| Jun 30, 2022 | -290.29 Mn |
| Mar 31, 2022 | -280.61 Mn |
| Dec 31, 2021 | -270.69 Mn |
| Sep 30, 2021 | -263.41 Mn |
| Jun 30, 2021 | -254.85 Mn |
| Mar 31, 2021 | -246.34 Mn |
| Dec 31, 2020 | -240.00 Mn |
| Sep 30, 2020 | -232.08 Mn |
| Jun 30, 2020 | -226.13 Mn |
| Mar 31, 2020 | -219.95 Mn |
| Dec 31, 2019 | -216.39 Mn |
| Sep 30, 2019 | -211.19 Mn |
| Jun 30, 2019 | -208.37 Mn |
| Mar 31, 2019 | -205.31 Mn |
| Dec 31, 2018 | -196.22 Mn |
| Sep 30, 2018 | -192.87 Mn |
| Jun 30, 2018 | -189.82 Mn |
| Mar 31, 2018 | -185.71 Mn |
| Dec 31, 2017 | -181.17 Mn |
| Sep 30, 2017 | -178.38 Mn |
| Jun 30, 2017 | -173.72 Mn |
| Mar 31, 2017 | -168.91 Mn |
| Dec 31, 2016 | -163.70 Mn |
| Sep 30, 2016 | -158.52 Mn |
| Jun 30, 2016 | -152.89 Mn |
| Mar 31, 2016 | -147.06 Mn |
| Dec 31, 2015 | -140.05 Mn |
| Sep 30, 2015 | -135.08 Mn |
| Jun 30, 2015 | -128.93 Mn |
| Mar 31, 2015 | -124.00 Mn |
| Dec 31, 2014 | -118.93 Mn |
| Sep 30, 2014 | -114.89 Mn |
| Jun 30, 2014 | -111.10 Mn |
| Mar 31, 2014 | 107.37 Mn |
| Dec 31, 2013 | -101.97 Mn |
| Sep 30, 2013 | 98.85 Mn |
| Jun 30, 2013 | 95.13 Mn |
| Mar 31, 2013 | 83.49 Mn |
| Dec 31, 2012 | 80.02 Mn |
| Sep 30, 2012 | 77.31 Mn |
| Jun 30, 2012 | 74.33 Mn |
| Mar 31, 2012 | 71.34 Mn |
| Dec 31, 2011 | 69.14 Mn |
| Sep 30, 2011 | 65.42 Mn |
| Jun 30, 2011 | 63.08 Mn |
| Dec 31, 2010 | 56.42 Mn |